Plain-English translation of NCT07652658 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new drug called AZD8965 to see if it can help slow or stop lung scarring in people with idiopathic pulmonary fibrosis (IPF). Participants will receive either the medication at one of three doses or a placebo (a dummy pill with no active ingredient) for 24 weeks. Some people in the study may already be taking approved IPF medicines, while others may not be on any treatment yet.
Current IPF treatments help some patients, but doctors are looking for better ways to slow the disease and give people more options. This study will help determine whether this new medication works, is safe, and might benefit people living with this serious lung condition.
You likely qualify if…
You likely don't qualify if…
You will visit a study site regularly over 24 weeks and receive either the new medication or a placebo as a pill to take. The study is 'double-blind,' meaning neither you nor the research team will know which treatment you're getting, so everyone is treated fairly. During your visits, doctors will check how you're doing, perform breathing tests, and monitor your health to see how well the treatment works and whether you experience any side effects.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
United States